We are live on
!
Find out more
ORPH
Orphazyme A/S
ORPH
ORPH
Delisted
ORPH was delisted on the 30th of March, 2022.
20 hedge funds and large institutions have $3.31M invested in Orphazyme A/S in 2021 Q4 according to their latest regulatory filings, with 3 funds opening new positions, 7 increasing their positions, 8 reducing their positions, and 5 closing their positions.
New
Increased
Maintained
Reduced
Closed
300% more call options, than puts
Call options by funds: $1.54M | Put options by funds: $384K
9% less funds holding
Funds holding: 22 → 20 (-2)
13% less repeat investments, than reductions
Existing positions increased: 7 | Existing positions reduced: 8
26% less capital invested
Capital invested by funds: $4.47M → $3.31M (-$1.16M)
40% less first-time investments, than exits
New positions opened: 3 | Existing positions closed: 5
Holders
20
Holders Change
-2
Holders Change %
-9.09%
% of All Funds
0.31%
Holding in Top 10
–
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
–
New
3
Increased
7
Reduced
8
Closed
5
Calls
$1.54M
Puts
$384K
Net Calls
+$1.15M
Net Calls Change
+$1.07M
Top Buyers
| 1 |
Renaissance Technologies
New York
|
+$576K |
| 2 |
Geode Capital Management
Boston,
Massachusetts
|
+$535K |
| 3 |
PA
Profund Advisors
Bethesda,
Maryland
|
+$450K |
| 4 |
Citadel Advisors
Miami,
Florida
|
+$335K |
| 5 |
UBS Group
Zurich,
Switzerland
|
+$237K |
